Asia-Pacific indapamide market is estimated to grow significantly at a CAGR of around 3.8% during the forecast period owing to the increasing prevalence of chronic disorders, including hypertension, CVD, and diabetes. The rising incidences of these diseases have been reported in several countries of Asia-Pacific, including China, India, and Singapore. For instance, in India, one in five young adults has high blood pressure, according to the data presented at the 70th Annual Conference of the Cardiological Society of India (CSI) held from November 22nd- 25th 2018. Browse Full Report at https://www.omrglobal.com/industry-reports/asia-pacific-indapamide-market